Pal Pritish Chandra, Bali Ashish, Boyapati Ramanarayana, Show Sangita, Tejaswi Kanikanti Siva, Khandelwal Sourabh
Department of Periodontology, Pacific Dental College and Hospital, PAHER University, Udaipur, India.
Department of Periodontology, Sibar Institute of Dental Sciences, Takkellapadu, Guntur, India.
J Yeungnam Med Sci. 2022 Oct;39(4):322-331. doi: 10.12701/jyms.2022.00325. Epub 2022 Sep 2.
The combined use of biomaterials for regeneration may have great biological relevance. This study aimed to compare the regenerative potential of biphasic calcium phosphate (BCP) alone and with growth factor enamel matrix derivatives (EMDs) for the regeneration of intrabony defects at 1 year.
This randomized controlled trial included 40 sites in 29 patients with stage II/III periodontitis and 2/3 wall intrabony defects that were treated with BCP alone (control group) or a combination of BCP and EMD (test group). BCP alloplastic bone grafts provide better bio-absorbability and accelerate bone formation. EMDs are commercially available amelogenins. Mean values and standard deviations were calculated for the following parameters: plaque index (PI), papillary bleeding index (PBI), vertical probing pocket depth (V-PPD), vertical clinical attachment level (V-CAL), and radiographic defect depth (RDD). Student paired and unpaired t-tests were used to compare the data from baseline to 12 months for each group and between the groups, respectively. The results were considered statistically significant at p<0.05.
At 12 months, the PI and PBI scores of the control and test groups were not significantly different (p>0.05). The mean V-PPD difference, V-CAL gain, and RDD difference were statistically significant in both groups at 12 months (p<0.001 for all parameters). Intergroup comparisons showed that the mean V-PPD reduction (2.13±1.35 mm), V-CAL gain (2.53±1.2 mm), and RDD fill (1.33±1.0 mm) were statistically significant between the groups at 12 months (p<0.001 for all parameters).
BCP and EMDs combination is a promising modality for the regeneration of intrabony defects.
生物材料联合用于再生可能具有重大的生物学意义。本研究旨在比较单独使用双相磷酸钙(BCP)以及联合生长因子釉基质衍生物(EMD)在1年后对骨内缺损进行再生的潜力。
这项随机对照试验纳入了29例患有II/III期牙周炎且存在2/3壁骨内缺损的患者的40个位点,分别采用单独BCP治疗(对照组)或BCP与EMD联合治疗(试验组)。BCP异体骨移植材料具有更好的生物吸收性并能加速骨形成。EMD是市售的釉原蛋白。计算以下参数的均值和标准差:菌斑指数(PI)、龈乳头出血指数(PBI)、垂直探诊袋深度(V-PPD)、垂直临床附着水平(V-CAL)和影像学缺损深度(RDD)。分别使用学生配对t检验和非配对t检验来比较每组从基线到12个月的数据以及两组之间的数据。结果在p<0.05时被认为具有统计学意义。
在12个月时,对照组和试验组的PI和PBI评分无显著差异(p>0.05)。两组在12个月时的平均V-PPD差异、V-CAL增加量和RDD差异均具有统计学意义(所有参数p<0.001)。组间比较显示,在12个月时,两组间平均V-PPD降低(2.13±1.35 mm)、V-CAL增加(2.53±1.2 mm)和RDD填充(1.33±1.0 mm)均具有统计学意义(所有参数p<0.001)。
BCP与EMD联合是一种有前景的骨内缺损再生治疗方式。